Darren K. McGuire

104.9k total citations · 31 hit papers
461 papers, 40.0k citations indexed

About

Darren K. McGuire is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Darren K. McGuire has authored 461 papers receiving a total of 40.0k indexed citations (citations by other indexed papers that have themselves been cited), including 290 papers in Endocrinology, Diabetes and Metabolism, 203 papers in Cardiology and Cardiovascular Medicine and 120 papers in Surgery. Recurrent topics in Darren K. McGuire's work include Diabetes Treatment and Management (244 papers), Diabetes Management and Research (100 papers) and Metabolism, Diabetes, and Cancer (92 papers). Darren K. McGuire is often cited by papers focused on Diabetes Treatment and Management (244 papers), Diabetes Management and Research (100 papers) and Metabolism, Diabetes, and Cancer (92 papers). Darren K. McGuire collaborates with scholars based in United States, Canada and United Kingdom. Darren K. McGuire's co-authors include James A. de Lemos, Deepak L. Bhatt, Lawrence A. Leiter, Ofri Mosenzon, Amit Khera, Stephen D. Wiviott, Marc S. Sabatine, Mark H. Drazner, John Wilding and Avivit Cahn and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Darren K. McGuire

441 papers receiving 39.1k citations

Hit Papers

Dapagliflozin and Cardiovascu... 2003 2026 2010 2018 2018 2013 2018 2015 2020 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    2018 4.3k citations Stephen D. Wiviott, Marc P. Bonaca et al. New England Journal of Medicine profile →
  2. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    2013 2.5k citations Benjamin M. Scirica, Deepak L. Bhatt et al. New England Journal of Medicine profile →
  3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
    2018 1.9k citations Thomas A. Zelniker, Stephen D. Wiviott et al. profile →
  4. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    2015 1.9k citations Jennifer B. Green, Paul W. Armstrong et al. New England Journal of Medicine profile →
  5. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
    2020 1.2k citations Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine profile →
  6. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
    2020 1.0k citations Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine profile →
  7. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
    2017 913 citations Aidin Rawshani, Araz Rawshani et al. New England Journal of Medicine profile →
  8. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    2018 898 citations Aidin Rawshani, Araz Rawshani et al. New England Journal of Medicine profile →
  9. B-type natriuretic peptide in cardiovascular disease
    2003 845 citations James A. de Lemos, Darren K. McGuire et al. profile →
  10. Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population
    2010 842 citations James A. de Lemos, Mark H. Drazner et al. profile →
  11. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
    2020 789 citations Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine profile →
  12. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
    2018 756 citations Julio Rosenstock, Vlado Perkovic et al. profile →
  13. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
    2020 708 citations Darren K. McGuire, Weichung Shih et al. profile →
  14. Race and Gender Differences in C-Reactive Protein Levels
    2005 603 citations Amit Khera, Darren K. McGuire et al. profile →
  15. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
    2014 545 citations Benjamin M. Scirica, Itamar Raz et al. Circulation profile →
  16. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
    2019 534 citations Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation profile →
  17. Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults
    2012 492 citations Scott M. Grundy, Amit Khera et al. profile →
  18. Metformin in Patients With Type 2 Diabetes and Kidney Disease
    2014 419 citations Silvio E. Inzucchi, Clifford J. Bailey et al. profile →
  19. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
    2017 409 citations Darren K. McGuire, Bernard Zinman et al. New England Journal of Medicine profile →
  20. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
    2019 394 citations Julio Rosenstock, Steven E. Kahn et al. profile →
  21. Type 1 Diabetes Mellitus and Cardiovascular Disease
    2014 394 citations Vivian Fonseca, Nikolaus Marx et al. Circulation profile →
  22. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults
    2013 374 citations Anand Rohatgi, Jarett D. Berry et al. profile →
  23. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks
    2019 363 citations Naveed Sattar, Araz Rawshani et al. Circulation profile →
  24. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
    2020 313 citations Thomas A. Zelniker, Marc P. Bonaca et al. Circulation profile →
  25. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
    2017 305 citations Phillip Banks, John B. Buse et al. New England Journal of Medicine profile →
  26. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
    2019 243 citations Silvio E. Inzucchi, Christopher P. Cannon et al. Circulation profile →
  27. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
    2022 223 citations Naveed Sattar, Darren K. McGuire et al. profile →
  28. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
    2023 120 citations Deepak L. Bhatt, John B. Buse et al. American Heart Journal profile →
  29. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    2025 89 citations Darren K. McGuire, Nikolaus Marx et al. New England Journal of Medicine profile →
  30. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity
    2025 20 citations Matthew M.Y. Lee, Nazim Ghouri et al. Diabetes Care profile →
  31. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
    2025 17 citations Erin D. Michos, Darren K. McGuire et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Darren K. McGuire United States 85 25.8k 14.1k 10.7k 9.8k 3.8k 461 40.0k
Silvio E. Inzucchi United States 85 32.3k 1.2× 9.2k 0.7× 12.0k 1.1× 13.6k 1.4× 4.3k 1.1× 416 44.4k
Lawrence A. Leiter Canada 95 23.6k 0.9× 7.7k 0.6× 14.4k 1.4× 9.5k 1.0× 3.3k 0.9× 544 40.0k
Neil R Poulter United Kingdom 74 15.6k 0.6× 15.8k 1.1× 9.0k 0.8× 4.7k 0.5× 2.7k 0.7× 444 35.3k
Rury R. Holman United Kingdom 76 29.6k 1.1× 5.7k 0.4× 9.2k 0.9× 10.7k 1.1× 3.7k 1.0× 350 40.3k
Peter Rossing Denmark 88 23.0k 0.9× 10.7k 0.8× 7.4k 0.7× 8.5k 0.9× 3.1k 0.8× 751 40.8k
Bernard Zinman Canada 106 44.5k 1.7× 8.9k 0.6× 18.0k 1.7× 18.6k 1.9× 5.3k 1.4× 652 63.6k
Steven E. Nissen United States 73 14.8k 0.6× 11.6k 0.8× 18.9k 1.8× 7.4k 0.8× 3.4k 0.9× 397 39.9k
Faı̈ez Zannad France 102 19.2k 0.7× 38.6k 2.7× 10.2k 1.0× 7.7k 0.8× 2.9k 0.8× 958 57.7k
William C. Cushman United States 62 15.0k 0.6× 22.6k 1.6× 5.9k 0.6× 3.5k 0.4× 2.7k 0.7× 265 39.3k
Marja‐Riitta Taskinen Finland 100 24.4k 0.9× 11.6k 0.8× 16.8k 1.6× 8.8k 0.9× 8.7k 2.3× 571 46.0k

Countries citing papers authored by Darren K. McGuire

Since Specialization
Citations

This map shows the geographic impact of Darren K. McGuire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren K. McGuire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren K. McGuire more than expected).

Fields of papers citing papers by Darren K. McGuire

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren K. McGuire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren K. McGuire. The network helps show where Darren K. McGuire may publish in the future.

Co-authorship network of co-authors of Darren K. McGuire

This figure shows the co-authorship network connecting the top 25 collaborators of Darren K. McGuire. A scholar is included among the top collaborators of Darren K. McGuire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren K. McGuire. Darren K. McGuire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Matthew M.Y., Nazim Ghouri, Anoop Misra, et al.. (2025). Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care. 48(3). 489–493. 20 indexed citations breakdown →
2.
3.
Farr, Maryjane, Patrick J. O’Hara, Nicholas Hendren, et al.. (2024). Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients. The Journal of Heart and Lung Transplantation. 44(4). 477–486.
4.
Rawshani, Araz, Araz Rawshani, Björn Eliasson, et al.. (2024). Non-coronary peripheral arterial complications in people with type 2 diabetes: a Swedish retrospective cohort study. The Lancet Regional Health - Europe. 39. 100888–100888. 3 indexed citations
5.
Handelsman, Yehuda, Javed Butler, George L. Bakris, et al.. (2023). Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and its Complications. 37(2). 108389–108389. 43 indexed citations
6.
Regan, Jessica A., Robert J. Mentz, Jennifer B. Green, et al.. (2023). Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 8(17). 9 indexed citations
7.
Bode, Bruce W., Eda Cengiz, R. Paul Wadwa, et al.. (2020). Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study. Diabetes Technology & Therapeutics. 23(1). 59–69. 16 indexed citations
8.
Cosentino, Francesco, Christopher P. Cannon, David Z.I. Cherney, et al.. (2020). Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation. 142(23). 2205–2215. 175 indexed citations
9.
Bhatt, Deepak L., Michael Szarek, Philippe Gabríel Steg, et al.. (2020). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine. 384(2). 117–128. 1204 indexed citations breakdown →
10.
Bhatt, Deepak L., Michael Szarek, Bertram Pitt, et al.. (2020). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 384(2). 129–139. 789 indexed citations breakdown →
11.
Zelniker, Thomas A., Marc P. Bonaca, Remo H.M. Furtado, et al.. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 141(15). 1227–1234. 313 indexed citations breakdown →
12.
Furtado, Remo H.M., Marc P. Bonaca, Itamar Raz, et al.. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 139(22). 2516–2527. 235 indexed citations
13.
Zelniker, Thomas A., David A. Morrow, Ofri Mosenzon, et al.. (2019). Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58. Circulation. 2 indexed citations
14.
Sattar, Naveed, Araz Rawshani, Stefan Franzén, et al.. (2019). Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 139(19). 2228–2237. 363 indexed citations breakdown →
15.
Zelniker, Thomas A., Stephen D. Wiviott, Itamar Raz, et al.. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 139(17). 2022–2031. 534 indexed citations breakdown →
16.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361. 112 indexed citations
17.
Bohula, Erin A., Benjamin M. Scirica, Christina Fanola, et al.. (2018). Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American Heart Journal. 202. 39–48. 10 indexed citations
18.
Abdullah, Shuaib, Laura F. DeFina, David Léonard, et al.. (2018). Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. Circulation. 138(21). 2315–2325. 178 indexed citations
19.
Rawshani, Aidin, Araz Rawshani, Stefan Franzén, et al.. (2017). Range of Risk Factor Levels. Circulation. 135(16). 1522–1531. 104 indexed citations
20.
Abdallah, Mouin, et al.. (2014). Patterns and Predictors of Intensive Statin Therapy Among Patients With Diabetes Mellitus After Acute Myocardial Infarction. The American Journal of Cardiology. 113(8). 1267–1272. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silvio E. Inzucchi Breakdown of academic impact, for papers by Lawrence A. Leiter Breakdown of academic impact, for papers by Neil R Poulter Breakdown of academic impact, for papers by Rury R. Holman Breakdown of academic impact, for papers by Peter Rossing Breakdown of academic impact, for papers by Bernard Zinman Breakdown of academic impact, for papers by Steven E. Nissen Breakdown of academic impact, for papers by Faı̈ez Zannad Breakdown of academic impact, for papers by William C. Cushman Breakdown of academic impact, for papers by Marja‐Riitta Taskinen
Rankless by CCL
2026